ArticleeGastroenterology2026
Unified platform for multiplex immunofluorescence across liver tissues and engineered models.
Article in eGastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiplex immunostaining combined with digital image analysis has become a central tool in hepatology research because it allows for the simultaneous visualisation and spatial mapping of multiple cellular markers within a single tissue section, providing critical insights into the complex, heterogeneous microenvironments of liver diseases like cholangiopathies, hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis or hepatic fibrosis. Nevertheless, significant barriers prevent the widespread adoption of most multiplexing platforms, including the technological complexity that necessitates specialised equipment and personnel. Additionally, several technologies remain incompatible with standard laboratory workflows and archival formalin-fixed paraffin-embedded (FFPE) tissue or in vitro culture samples. Methods: We developed a customised immunofluorescence workflow based on sequential cycles of antibody stripping to generate multiplexed digital images from FFPE liver sections, intrahepatic cholangiocyte organoids and primary mouse liver cells cultured either in conventional two-dimensional systems or within a biliary niche-on-a-chip platform. Subsequent image processing and channel alignment were performed using an in-house and open-source, Python-based software tool. Results: We demonstrate the functionality of a multiplex immunofluorescence protocol that can be readily adapted to a broad range of archival tissues and primary cell-based samples. This workflow allows the visualisation of antigen-expressing cells and protein-protein interactions using proximity ligation assays. This study also details the technical considerations necessary for its rapid integration into routine workflows in virtually any laboratory equipped for conventional immunohistochemistry. Conclusions: This methodology integrates multiplex immunofluorescence into standard laboratory workflows, thereby enabling researchers to overcome challenges such as technological complexity and cost for transitioning from conventional to multiplexed microscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.